Syncromune®

Overview

Syncromune® Inc. is a clinical-stage biopharmaceutical company based in Fort Lauderdale, Florida, founded in 2020. The company specializes in developing novel intratumoral immunotherapies aimed at treating solid tumors, particularly metastatic solid tumor cancers. Its flagship technology, SYNC-T®, is a personalized, in situ combination therapy that utilizes partial oncolysis followed by the infusion of a multi-target biologic drug directly into the tumor. This innovative approach is designed to stimulate the immune system to recognize and attack cancer cells throughout the body.

The company's pipeline includes drug candidates such as SV-102, which is undergoing clinical trials for metastatic castration-resistant prostate cancer. Syncromune has secured substantial funding, including a $100 million Series A round, to support its clinical programs. It holds an exclusive license agreement with Eucure Biopharma to develop and commercialize YH002, an OX40 antibody, and other active ingredients. Focused on intratumoral immuno-oncology, the company aims to deliver life-changing treatments to patients with unmet medical needs.

Basic Information

Contact Details

• Phone: +1 518-796-6110
• Website: syncromune.com
• LinkedIn: linkedin.com/company/syncromune

Key Focus Areas & Initiatives

• cancer vaccine
• immunotherapy
• metastatic solid tumors
• mcrpc
• multitarget biologic drug
• combination cancer therapy
• prostate cancer
• breast cancer
• lung cancer
• bladder cancer
• cervical cancer
• renal cancer
• head & neck cancer
• intratumoral immunotherapy
• in situ cancer vaccine
• biotechnology research
• immune checkpoint
• immune suppression mechanisms
• multi-target immunotherapy
• pharmaceuticals
• locoregional therapy
• immune suppression reversal
• in situ cancer therapy
• immune response in metastatic cancer
• immune memory in cancer
• immune memory
• immune modulation
• immune activation in lymphatics
• personalized immunotherapy
• immune response
• systemic anti-tumor response
• personalized cancer vaccine
• personalized in situ therapy
• multi-target biologic drugs
• immune system stimulation
• immune activation
• combination immunotherapy
• biologic drug infusion
• immune suppression in tme
• oncology
• t cell activation
• tumor microenvironment
• locoregional immunotherapy
• biotechnology
• combination multi-target approach
• cancer immunotherapy
• cry-immune vaccination
• cryotherapy in cancer
• biologic drugs
• healthcare
• immune suppression
• solid tumor treatment
• locoregional delivery
• immune system activation
• tumor oncolysis
• services
• research and development in the physical, engineering, and life sciences
• medical
• hospital & health care
• health care
• health, wellness & fitness

Technologies Used

• CloudFlare Hosting
• Google Font API
• Google Tag Manager
• Mobile Friendly
• Outlook
• Remote
• Route 53
• Shutterstock
• Vimeo
• WordPress.org
• YouTube